The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α
Authors:
- 1 May 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (6) , 1224-1231
Abstract
Background. Anti–tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and othKeywords
This publication has 25 references indexed in Scilit:
- Molecular mechanisms of necroptosis: an ordered cellular explosionNature Reviews Molecular Cell Biology, 2010
- Transmembrane TNF- : structure, function and interaction with anti-TNF agentsRheumatology, 2010
- Trying to Reconcile Genetic Findings with Resistance to Lymphocyte Apoptosis in Crohn’s Disease PathogenesisDigestion, 2010
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implicationsGut, 2006
- Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-αNature, 1997
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- Two tumour necrosis factor receptors: structure and functionTrends in Cell Biology, 1995
- A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNFCell, 1988
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984